Successful use of secukinumab in pustular psoriasis

Successful use of secukinumab in pustular psoriasis

BSA: body surface area DLQI: Dermatology Life Quality Index IL-17A: interleukin-17A PASI: Psoriasis Area and Severity Index INTRODUCTION Psoriasis is a common chronic immunologic condition of the skin and nails that affects approximately 2% of the population and is characterized by red elevated plaques with silvery scale. Various forms exist, of which, chronic plaque psoriasis is most common, o...

Secukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report.

Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation.

We present a 34-year-old female patient with methotrexate unresponsive longstanding plaque psoriasis who developed pustular psoriasis ten weeks after initiation of ustekinumab therapy. Given the lack of other side effects and the rapid initial response of the underlying plaque psoriasis, we opted against discontinuing ustekinumab therapy. Topical corticosteroids were added for the management of...

Two Cases of Generalized Pustular Psoriasis: Successful Treatment with Infliximab

Vol. 26, No. 6, 2014 787 Received September 12, 2013, Revised January 28, 2014, Accepted for publication February 1, 2014 Corresponding author: Byung-Soo Kim, Department of Dermatology, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: 82-51-240-7338, Fax: 82-51-245-9467, E-mail: [email protected] This is an Open Access article distributed under the terms of...

Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab.

2nd and 3rd infusions ( fig. 1 e and f). However, treatment with infliximab was discontinued due to an infusion-related reaction with polyarthalgia, myalgia and fever after the 3rd infusion. Although acitretin (30 mg daily) was reintroduced, some painful pustular skin lesions, erythema, fissuring and scaling started reappearing on her feet approximately 8 weeks after the 3rd infusion with infli...